Tilmanocept

Summary

Tilmanocept (CHEMBL5315077) is an approved small molecule; indicated across 2 conditions including endometrium neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5315077
Name	Tilmanocept
Type	Small molecule
Max phase	4

Also known as: Lymphoseek, Tilmanocept, TILMANOCEPT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
endometrium neoplasm	2	MONDO:0021251	MONDO:0011962

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE2	7
PHASE4	3
PHASE3	3
PHASE1	3
EARLY_PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02287675	PHASE4	COMPLETED	Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer
NCT04261179	PHASE4	UNKNOWN	Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer
NCT04487912	PHASE4	WITHDRAWN	Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer
NCT00671918	PHASE3	COMPLETED	Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma
NCT00911326	PHASE3	TERMINATED	Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
NCT01106040	PHASE3	COMPLETED	Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes
NCT01902953	PHASE2	COMPLETED	Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
NCT02509585	PHASE2	TERMINATED	A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection
NCT02509598	PHASE2	COMPLETED	A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping
NCT02857608	PHASE2	WITHDRAWN	A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus
NCT03405142	PHASE2	COMPLETED	Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
NCT04511026	PHASE2	TERMINATED	Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
NCT04947137	PHASE2	COMPLETED	Development of a Normative Database for Rheumatoid Arthritis (RA) Imaging With Tc99m Tilmanocept
NCT02683421	PHASE1	COMPLETED	Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging
NCT03241446	PHASE1	WITHDRAWN	Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
NCT04096716	PHASE1	TERMINATED	Mapping Draining Lymph Nodes in CNS Malignancies
NCT04663126	EARLY_PHASE1	TERMINATED	Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma
NCT02065232	Not specified	COMPLETED	Sentinel Lymph Node Mapping Post-Injection Site Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).